EUVIMEDEUVIMED entdecken
Crossref

IgAN.pt: External Validation of theInternational IgA Nephropathy PredictionTool in a Portuguese Cohort

Beatriz Cortez Ferreira, Pedro Fragoso, Beatriz Fernandes, Ana Galvão, Andreia Borges, Luís Miguel Amaral Rodrigues, Alves, Rui, Helena Sá

Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · 11.10.2025

DOI: 10.71749/pkj.116 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT), erschienen am 11.10.2025. Verfasst von Beatriz Cortez Ferreira und 8 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

IgA nephropathy (IgAN) is one of the most common primary glomerulonephritis worldwide, presenting with highly variable clinical manifestations and disease progression. The 10‑year risk of end‑stage kidney disease (ESKD) ranges from 5% to 60%, making risk stratification a major challenge. To address this, the IgAN‑Prediction Tool (IgAN‑PT) was developed and is currently recommended for risk assessment.

Methods

This study aimed to evaluate the applicability of the IgAN-PT in a Portuguese cohort. We conducted a retrospective analysis of all biopsy‑confirmed IgAN cases from January 1998 to December 2018 and assessed the tool’s predictive performance.

Results

In a cohort of 93 Portuguese patients, the IgAN‑PT significantly correlated with 5‑year progression to ESKD or a ≥50% reduction in eGFR (OR 1.06; 95%CI [1.02‑1.1]), demonstrating good discriminative performance (AUC 0.75; 95%CI [0.681‑0.910]). Additionally, baseline proteinuria >1.4 g/24h, eGFR 12.4% provided the best sensitivity‑specificity compromise for predicting the primary outcome. A multivariate model incorporating both IgAN‑PT and the presence of crescents showed improved predictive capacity compared with IgAN‑PT alone (AUC 0.845; 95%CI [0.754‑0.937]).

Conclusion

Our findings validate the use of IgAN‑PT in a Portuguese cohort and suggest that incorporating the presence of crescents enhances its predictive accuracy.

Schlagwörter

IgA nephropathyexternal validationend-stage renal diseaserisk stratificationglomerular crescentsestimated glomerular filtration rate declineproteinuriaprimary glomerulonephritisPortuguese patients

Zitieren

APA

Ferreira, B. C., Fragoso, P., Fernandes, B., Galvão, A., Borges, A., Rodrigues, L. M. A., Alves, Rui, & Sá, H. (2025). IgAN.pt: External Validation of theInternational IgA Nephropathy PredictionTool in a Portuguese Cohort. Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT). https://doi.org/10.71749/pkj.116

Vancouver

Ferreira BC, Fragoso P, Fernandes B, Galvão A, Borges A, Rodrigues LMA, et al. IgAN.pt: External Validation of theInternational IgA Nephropathy PredictionTool in a Portuguese Cohort. Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT). 2025. doi:10.71749/pkj.116

BibTeX
@article{Ferreira2025,
  author = {Ferreira, Beatriz Cortez and Fragoso, Pedro and Fernandes, Beatriz and Galvão, Ana and Borges, Andreia and Rodrigues, Luís Miguel Amaral and Alves and Rui and Sá, Helena},
  title = {IgAN.pt: External Validation of theInternational IgA Nephropathy PredictionTool in a Portuguese Cohort},
  journal = {Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)},
  year = {2025},
  doi = {10.71749/pkj.116}
}
Kostenlos starten →